CRISPR Therapeutics AG CRSP

With headquarters in Zug, Switzerland, CRISPR Therapeutics AG (CRSP) is a gene-editing company. Founded in 2013, the firm develops gene-based medicines to treat patients with serious diseases. As of August 2020, the company was working on other programmes, including hemoglobinopathies, immuno-oncology, regenerative medicine and in vivo approaches. The company has offices in San Francisco, California and Cambridge, Massachusetts in the US, as well as an office in Switzerland and a business office in London.

Trading on the NASDAQ stock exchange, the ticker CRSP has been assigned to CRISPR Therapeutics AG. From October 2016 to August 2020, the CRSP share price reached a low of $11.63 (February 2017) and rose to a high of $97.82 (July 2020).

The company makes use of CRISPR/Cas9 gene-editing technology to modify, delete or correct specific regions of human DNA. This technology was co-invented by Dr Emmanuelle Charpentier, one of CRISPR Therapeutics AG's scientific founders. Genes are edited by precisely cutting DNA and allowing natural DNA repair processes to complete the job. CRISPR Therapeutics AG's lead programme targets β-thalassemia and sickle cell disease. It entered clinical testing in August 2020.

Track the CRSP instrument by adding it to your eToro watchlist now and diversify your portfolio with this medical research company.